Last C$0.70 CAD
Change Today -0.04 / -5.41%
Volume 22.8K
IMV On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 11:09 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

immunovaccine inc (IMV) Snapshot

Open
C$0.74
Previous Close
C$0.74
Day High
C$0.74
Day Low
C$0.69
52 Week High
02/7/14 - C$1.50
52 Week Low
12/31/13 - C$0.38
Market Cap
64.2M
Average Volume 10 Days
113.6K
EPS TTM
--
Shares Outstanding
91.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOVACCINE INC (IMV)

Related News

No related news articles were found.

immunovaccine inc (IMV) Related Businessweek News

No Related Businessweek News Found

immunovaccine inc (IMV) Details

Immunovaccine Inc., a clinical-stage biopharmaceutical company, discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The company develops its products based on DepoVax vaccine-adjuvanting platform, a vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Its product candidates include DPX-Survivac, a therapeutic cancer vaccine, which has completed Phase I clinical trials for the treatment of ovarian and brain cancer; and DPX-0907, a therapeutic cancer vaccine that has completed Phase I clinical trials for the treatment of breast, ovarian, and prostate cancer. The company also develops pre-clinical stage vaccine product candidates for infectious diseases, including respiratory syncytial virus and anthrax. In addition, its product pipeline consists of DepoVax-validating partnered programs for addiction medicine and animal health. Immunovaccine Inc. was founded in 2000 and is headquartered in Halifax, Canada.

21 Employees
Last Reported Date: 11/14/14
Founded in 2000

immunovaccine inc (IMV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: C$200.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$128.8K
Compensation as of Fiscal Year 2013.

immunovaccine inc (IMV) Key Developments

Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer

Immunovaccine Inc. announced that DPX-Survivac, the Company's lead cancer vaccine candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as maintenance therapy in subjects with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. Ovarian cancer patients who have no measurable disease following their initial standard surgery and chemotherapy treatments have an unmet need that may be served by the DPX-Survivac therapy. DPX-Survivac is designed to activate T cells of the immune system that are expected to recognize and eliminate cancer cells in an attempt to keep patients in remission longer. The FDA's Fast Track program is designed to facilitate the development and expedite the review of new drugs with the potential to treat serious or life-threatening conditions and address an unmet medical need. This designation provides companies the opportunity for more frequent interactions with FDA during clinical development and the "rolling" submission of individual sections of a Biologics License Application (BLA) as they are completed for review by FDA. Additionally, therapies with Fast Track designation are eligible for priority review and/or accelerated approval, which have the potential to reduce the time required for FDA review and make a therapy available to patients earlier than would be traditionally possible. Immunovaccine has previously reported positive results from DPX-Survivac clinical studies in ovarian cancer patients. In these studies, robust and durable CD8 T cell responses were observed in almost all patients receiving a specified regimen of the vaccine. The vast majority of ovarian cancer patients enrolled in these studies were in remission with no evidence of disease. Notably, a patient with stable but measurable disease achieved a partial response (PR) as measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1). The PR, which persisted following discontinuation of treatment, was accompanied by reduction in levels of a commonly used ovarian cancer biomarker (CA125) and a significant increase in vaccine-induced immune responses. The patient benefited from the DPX-Survivac therapy for more than 8 months demonstrating a potentially durable effect of the therapy. Immunovaccine is finalizing the design of a large randomized Phase II trial in ovarian cancer to be sponsored and conducted by Canada'sNCIC Clinical Trials Group. The company also recently announced that it has received clearance from Health Canada to conduct a Phase II clinical study of DPX-Survivac in patients with diffuse large B cell lymphoma (DLBCL). The Company-sponsored trial, expected to begin in early 2015, will evaluate DPX-Survivac in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. Immunovaccine expects initial data from this study in the second half of 2015. Positive trial results could provide rationale for the initiation of a pivotal trial in recurrent DLBCL which could lead to the approval of DPX-Survivac for the treatment of DLBCL.

Health Canada Clears Immunovaccine to Conduct Phase II Clinical Trial of Dpx-Survivac in Recurrent Lymphoma

Immunovaccine Inc. announced that it has received clearance from Health Canada to conduct a Phase II clinical study of DPX-Survivac in patients with diffuse large B cell lymphoma (DLBCL). The Company-sponsored trial will evaluate DPX-Survivac, Immunovaccine's lead cancer vaccine candidate, in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. The study will be the first Phase II clinical trial specifically designed to evaluate the efficacy of DPX-Survivac. The open label trial will enroll up to 24 patients with recurrent survivin-expressing DLBCL with measurable disease. This will allow investigators to evaluate the clinical effect of DPX-Survivac in combination with oral cyclophosphamide and determine the clinical response rate in patients receiving the DPX-Survivac therapy. Investigators will also monitor immune responses and changes in tumor biopsies from these patients. Immunovaccine expects to have multiple clinical trial sites in Canada to ensure the efficient conduct of this trial. Immunovaccine expects that initial data from this study will be available in the second half of 2015. Positive trial results could provide rationale for the initiation of a pivotal trial in recurrent DLBCL. The DPX-Survivac therapy will be applied to patients who are not transplant candidates or who experience recurrence following a stem cell transplant and lack additional treatment options.

ImmunoVaccine Inc. Primary Exchange Listing has Changed to The Toronto Stock Exchange from TSX Venture Exchange

ImmunoVaccine Inc. primary exchange listing has changed to The Toronto Stock Exchange from TSX Venture Exchange.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMV:CN C$0.70 CAD -0.04

IMV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMV.
View Industry Companies
 

Industry Analysis

IMV

Industry Average

Valuation IMV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOVACCINE INC, please visit www.imvaccine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.